References
"Many years ago we purchased one of the first Flyscreen automated patch clamp devices, but only recent developments have introduced high success rates combined with a high degree of stability to the system. A few months ago (April 2009) we were satisfied enough to integrate the Flyscreen in our routine screening projects. In a current K+-channel assay we are obtaining up to 75% successful experiments with this technology."
(Dr. Carsten Strübing, Cardiovascular Discovery Research at Sanofi-Aventis)
"Our Flyscreen 8500 automated patch clamp screening system provides us with unique capabilities that are not available to us using our fluorescent-based or other high-throughput electrophysiological assay platforms. The ability to perform true gigaseal recordings, to apply critical electrophysiological compensations and to record either in normal whole-cell mode or the cytoplasm-preserving perforated-patch mode has enabled us measure ion channel targets which were previously beyond reach.
During our recent screening campaign, flyion provided a much needed additional capacity for compound evaluation. The dedication, flexibility and capable efforts of your (flyion's) in-house scientists were instrumental in our meeting critical milestones on time."
(George R. Ehring, Ph.D., Research Investigator at Allergan Inc.)